Geertje Van Der Horst, PhD, Leiden University Medical Centre, Leiden, The Netherlands, provides an overview of limitations in the use of oncolytic viral therapy, including optimal patient stratification, viral delivery, clinical endpoints, as well as the impact of previously existing immunity. Dr van der Horst highlights strategies under investigation to improve efficacy, including the use of a novel adenovirus that has no seroprevalence within human populations. This interview took place at the European Association of Urology (EAU) Meeting 2022.
